

Jonathan D Karnon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8722326/publications.pdf>

Version: 2024-02-01

176
papers

4,319
citations

172457

29
h-index

133252

59
g-index

179
all docs

179
docs citations

179
times ranked

6052
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicted cardiovascular disease risk and prescribing of antihypertensive therapy among patients with hypertension in Australia using MedicinesInsight. <i>Journal of Human Hypertension</i> , 2023, 37, 370-378.	2.2	5
2	Effectiveness of the Wearable Sensor-based Ambient Intelligent Geriatric Management (AmbiGeM) System in Preventing Falls in Older People in Hospitals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 155-163.	3.6	9
3	Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level Estimates. <i>Pharmacoeconomics</i> , 2022, 40, 31-43.	3.3	16
4	Pragmatic review of interventions to prevent inpatient hypoglycaemia. <i>Diabetic Medicine</i> , 2022, 39, e14737.	2.3	6
5	Cost effectiveness of a 1-hour high-sensitivity troponin-T protocol: An analysis of the RAPID-TnT trial. <i>IJC Heart and Vasculature</i> , 2022, 38, 100933.	1.1	3
6	Mapping a decade of interventions to address the supportive care needs of individuals living with or beyond cancer: a scoping review of reviews. <i>Supportive Care in Cancer</i> , 2022, 30, 3793.	2.2	5
7	The complexities, coordination, culture and capacities that characterise the delivery of oncology services in the common areas of ambulatory settings. <i>BMC Health Services Research</i> , 2022, 22, 190.	2.2	0
8	An Observational Study to Assess the Effectiveness of 4CMenB against Meningococcal Disease and Carriage and Gonorrhoea in Adolescents in the Northern Territory, Australiaâ€”Study Protocol. <i>Vaccines</i> , 2022, 10, 309.	4.4	3
9	Effect of a multi-faceted rapid response system re-design on repeat calling of the rapid response team. <i>PLoS ONE</i> , 2022, 17, e0265485.	2.5	1
10	Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 479-486.	2.1	10
11	Understanding current and projected emergency department presentations and associated healthcare costs in a changing thermal climate in Adelaide, South Australia. <i>Occupational and Environmental Medicine</i> , 2022, 79, 421-426.	2.8	3
12	Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 337-349.	2.1	6
13	Evaluating cost benefits from a heat health warning system in Adelaide, South Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2022, 46, 149-154.	1.8	5
14	Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	0
15	The long-term costs and effects of tubal flushing with oil-based versus water-based contrast during hysterosalpingography. <i>Reproductive BioMedicine Online</i> , 2021, 42, 150-157.	2.4	6
16	Extrapolation of Survival Curves Using Standard Parametric Models and Flexible Parametric Spline Models: Comparisons in Large Registry Cohorts with Advanced Cancer. <i>Medical Decision Making</i> , 2021, 41, 179-193.	2.4	14
17	Blood pressure control in Australian general practice: analysis using general practice records of 1.2 million patients from the MedicinesInsight database. <i>Journal of Hypertension</i> , 2021, 39, 1134-1142.	0.5	9
18	The representation of public values in health technology assessment to inform funding decisions: the case of Australia's national funding bodies. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e22.	0.5	4

#	ARTICLE	IF	CITATIONS
19	Prioritising models of healthcare service delivery for a more sustainable health system: a Delphi study of Australian health policy, clinical practice and management, academic and consumer stakeholders. <i>Australian Health Review</i> , 2021, 45, 425.	1.1	4
20	Embedding an economist in regional and rural health services to add value and reduce waste by improving local-level decision-making: protocol for the "embedded Economist"™ program and evaluation. <i>BMC Health Services Research</i> , 2021, 21, 201.	2.2	3
21	An integrated knowledge translation approach to address avoidable rehospitalisations and unplanned admissions for older people in South Australia: implementation and evaluation program plan. <i>Implementation Science Communications</i> , 2021, 2, 36.	2.2	4
22	Peer-led HIV care and the UNAIDS 90-90-90 treatment targets in Tigray, Ethiopia: a cluster randomised trial and economic evaluation of "teach-test-link-trace" model (TTLT) trial protocol. <i>BMJ Open</i> , 2021, 11, e043943.	1.9	0
23	Expediting Patient Access to New Health Technologies: Role of Disease-Specific Reference Models. <i>Value in Health</i> , 2021, 24, 755-758.	0.3	3
24	Increasing impacts of temperature on hospital admissions, length of stay, and related healthcare costs in the context of climate change in Adelaide, South Australia. <i>Science of the Total Environment</i> , 2021, 773, 145656.	8.0	25
25	Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1610-1621.	3.7	4
26	Characteristics of Quality Activities in a Tertiary Teaching Hospital in Western Australia. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	1.8	1
27	Improving cost-effectiveness of endoscopic surveillance for Barrett's esophagus by reducing low-value care: a review of economic evaluations. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 5905-5917.	2.4	4
28	Late Outcomes of the RAPID-TnT Randomized Controlled Trial: 0/1-Hour High-Sensitivity Troponin T Protocol in Suspected ACS. <i>Circulation</i> , 2021, 144, 113-125.	1.6	27
29	Providing outpatient cancer care for CALD patients: a qualitative study. <i>BMC Research Notes</i> , 2021, 14, 304.	1.4	2
30	Impact of heatwave intensity using excess heat factor on emergency department presentations and related healthcare costs in Adelaide, South Australia. <i>Science of the Total Environment</i> , 2021, 781, 146815.	8.0	18
31	Understanding the Impacts of Temperature on Hospital Admissions, Length of Stay, and Related Healthcare Costs under the Changing Climate. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	0
32	Healthcare Costs of Emergency Department Presentations Related to Heatwave Intensity and Severity. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	0
33	Access, Use, and Patient-Reported Experiences of Emergency Care During the COVID-19 Pandemic: Population-Based Survey. <i>JMIR Human Factors</i> , 2021, 8, e30878.	2.0	2
34	Strategies for Avoiding Neglect of Opportunity Costs by Decision-Makers. <i>Applied Health Economics and Health Policy</i> , 2021, , 1.	2.1	0
35	Hospital healthcare costs attributable to heat and future estimations in the context of climate change in Perth, Western Australia. <i>Advances in Climate Change Research</i> , 2021, 12, 638-648.	5.1	9
36	"Cost-effectiveness" in surgery: concepts of "cost-utility" analysis explained. <i>ANZ Journal of Surgery</i> , 2021, 91, 1717-1723.	0.7	10

#	ARTICLE	IF	CITATIONS
37	It's Not the Model, It's the Way You Use It: Exploratory Early Health Economics Amid Complexity Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". <i>International Journal of Health Policy and Management</i> , 2021, 10, 36-38.	0.9	4
38	Value assessment of antimicrobials and the implications for development, access, and funding of effective treatments: Australian stakeholder perspective. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e28.	0.5	1
39	Heat-attributable hospitalisation costs in Sydney: Current estimations and future projections in the context of climate change. <i>Urban Climate</i> , 2021, 40, 101028.	5.7	2
40	Clinical indications treated with unregistered antimicrobials: regulatory challenges of antimicrobial resistance and access to effective treatment for patients. <i>Australian Health Review</i> , 2020, 44, 263.	1.1	2
41	Improving Decision-Making Processes in Health: Is It Time for (Disease-Specific) Reference Models?. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 1-4.	2.1	5
42	Strategies for implementing shared decision making in elective surgery by health care practitioners: A systematic review. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 582-601.	1.8	16
43	Evaluations of healthcare delivery models in Australia. <i>JBIC Database of Systematic Reviews and Implementation Reports</i> , 2020, 18, 128-134.	1.7	1
44	Feasibility of de-linking reimbursement of antimicrobials from sales: the Australian perspective as a qualitative case study. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa023.	2.1	2
45	Scoping review of Australian evaluations of healthcare delivery models: are we making the most of the evidence?. <i>Australian Health Review</i> , 2020, 44, 557-562.	1.1	2
46	A scoping review of the economics of multidisciplinary teams in oncology care. <i>Journal of Cancer Policy</i> , 2020, 26, 100257.	1.4	7
47	Re-designing a rapid response system: effect on staff experiences and perceptions of rapid response team calls. <i>BMC Health Services Research</i> , 2020, 20, 480.	2.2	11
48	Costs and uptake of a community model of paediatric food allergy care versus specialist hospital care: A before-and-after controlled trial. <i>Journal of Paediatrics and Child Health</i> , 2020, 56, 1225-1232.	0.8	0
49	Estimating the utilisation of unregistered antimicrobials in Australia. <i>Infection, Disease and Health</i> , 2020, 25, 82-91.	1.1	0
50	Adjusting for Treatment Switching in Oncology Trials: A Systematic Review and Recommendations for Reporting. <i>Value in Health</i> , 2020, 23, 388-396.	0.3	14
51	The Economic Value of the Delivery of Primary Cleft Surgery in Timor Leste 2000-2017. <i>World Journal of Surgery</i> , 2020, 44, 1699-1705.	1.6	3
52	A Simple Decision Analysis of a Mandatory Lockdown Response to the COVID-19 Pandemic. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 329-331.	2.1	52
53	The Case for a Temporary COVID-19 Income Tax Levy Now, During the Crisis. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 335-337.	2.1	11
54	Cost-effectiveness analysis of imaging surveillance in stage II and III extremity soft tissue sarcoma: an Australian perspective. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 5.	1.5	7

#	ARTICLE	IF	CITATIONS
55	Should Health Economic Evaluations Undertaken from a Societal Perspective Include Net Government Spending Multiplier Effects?. <i>Applied Health Economics and Health Policy</i> , 2020, 18, 467-475.	2.1	1
56	Are the benefits of new health services greater than their opportunity costs?. <i>Australian Health Review</i> , 2019, 43, 508-510.	1.1	3
57	Behavioral Economic Insights to Improve Medication Adherence in Adults with Chronic Conditions: A Scoping Review. <i>Patient</i> , 2019, 12, 571-592.	2.7	8
58	A Randomized Trial of a 1-Hour Troponin T Protocol in Suspected Acute Coronary Syndromes. <i>Circulation</i> , 2019, 140, 1543-1556.	1.6	144
59	Structuring a conceptual model for cost-effectiveness analysis of frailty interventions. <i>PLoS ONE</i> , 2019, 14, e0222049.	2.5	11
60	Increasing trends in hospitalisations due to atrial fibrillation in Australia from 1993 to 2013. <i>Heart</i> , 2019, 105, 1358-1363.	2.9	51
61	Health related quality of life (HRQoL) among Aboriginal South Australians: a perspective using survey-based health utility estimates. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 39.	2.4	5
62	How much emergency department use by vulnerable populations is potentially preventable?: A period prevalence study of linked public hospital data in South Australia. <i>BMJ Open</i> , 2019, 9, e022845.	1.9	11
63	What is multidisciplinary cancer care like in practice? a protocol for a mixed-method study to characterise ambulatory oncology services in the Australian public sector. <i>BMJ Open</i> , 2019, 9, e031179.	1.9	4
64	in-DEPtH framework: evidence-informed, co-creation framework for the Design, Evaluation and Procurement of Health services. <i>BMJ Open</i> , 2019, 9, e026482.	1.9	3
65	Developing a Model of Care for Home Infusions of Natalizumab for People With Multiple Sclerosis. <i>Journal of Infusion Nursing</i> , 2019, 42, 289-296.	2.3	9
66	Behavioral economic insights to improve medication adherence in adults with chronic conditions. <i>JBI Database of Systematic Reviews and Implementation Reports</i> , 2019, 17, 1915-1923.	1.7	1
67	Determining Value in Health Technology Assessment: Stay the Course or Tack Away?. <i>Pharmacoeconomics</i> , 2019, 37, 293-299.	3.3	19
68	Effectiveness of an Ambient Intelligent Geriatric Management system (AmbiGeM) to prevent falls in older people in hospitals: protocol for the AmbiGeM stepped wedge pragmatic trial. <i>Injury Prevention</i> , 2019, 25, 157-165.	2.4	16
69	Economics of multidisciplinary teams in oncology. <i>JBI Evidence Synthesis</i> , 2019, Publish Ahead of Print, 1285-1291.	1.3	4
70	Cost-effectiveness of programmed cell death protein 1/programmed death-ligand 1 inhibitors (aPD1/aPDL1) varies widely.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18351-e18351.	1.6	0
71	COST-UTILITY ANALYSIS OF PRIVATE CONTRACTING TO REDUCE PUBLIC WAITING TIMES FOR JOINT REPLACEMENT SURGERY. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 147-155.	0.5	3
72	The political economy of the assessment of value of new health technologies. <i>Journal of Health Services Research and Policy</i> , 2018, 23, 116-122.	1.7	4

#	ARTICLE	IF	CITATIONS
73	Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System. <i>Pharmacoeconomics</i> , 2018, 36, 239-252.	3.3	153
74	Cost-effectiveness evaluation of the 45-49 year old health check versus usual care in Australian general practice: A modelling study. <i>PLoS ONE</i> , 2018, 13, e0207110.	2.5	7
75	Cost-effectiveness modelling of IVF in couples with unexplained infertility. <i>Reproductive BioMedicine Online</i> , 2018, 37, 555-563.	2.4	11
76	Oil-based or water-based contrast for hysterosalpingography in infertile women: a cost-effective analysis of a randomized controlled trial. <i>Fertility and Sterility</i> , 2018, 110, 754-760.	1.0	16
77	The never ending road: improving, adapting and refining a needs-based model to estimate future general practitioner requirements in two Australian states. <i>Family Practice</i> , 2018, 35, 193-198.	1.9	5
78	Model Structuring for Economic Evaluations of New Health Technologies. <i>Pharmacoeconomics</i> , 2018, 36, 1309-1319.	3.3	13
79	A long-term evaluation of the stage of change approach and compensable injury outcomes " a cluster-randomised trial. <i>Ergonomics</i> , 2017, 60, 628-635.	2.1	6
80	Screening for important unwarranted variation in clinical practice: a triple-test of processes of care, costs and patient outcomes. <i>Australian Health Review</i> , 2017, 41, 104.	1.1	22
81	Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme. <i>Australian Health Review</i> , 2017, 41, 1.	1.1	9
82	Is the Counterweight Program a feasible and acceptable option for structured weight management delivered by practice nurses in Australia? A mixed-methods study. <i>Australian Journal of Primary Health</i> , 2017, 23, 348.	0.9	4
83	A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 635-645.	2.1	10
84	Cost effectiveness of high-sensitivity troponin compared to conventional troponin among patients presenting with undifferentiated chest pain: A trial based analysis. <i>International Journal of Cardiology</i> , 2017, 238, 144-150.	1.7	17
85	Health State Utility Values for Cost-Effectiveness Models. <i>Pharmacoeconomics</i> , 2017, 35, 1-3.	3.3	16
86	Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread?. <i>Pharmacoeconomics</i> , 2017, 35, 1111-1112.	3.3	1
87	What will make a difference? Assessing the impact of policy and non-policy scenarios on estimations of the future GP workforce. <i>Human Resources for Health</i> , 2017, 15, 43.	3.1	8
88	Unconnected and out-of-sight: identifying health care non-users with unmet needs. <i>BMC Health Services Research</i> , 2017, 17, 80.	2.2	6
89	The stage of change approach for implementing ergonomics advice " Translating research into practice. <i>Applied Ergonomics</i> , 2017, 59, 225-233.	3.1	16
90	Effectiveness of preoperative medical consultations by internal medicine physicians: a systematic review. <i>BMJ Open</i> , 2017, 7, e018632.	1.9	15

#	ARTICLE	IF	CITATIONS
91	Sociodemographic variations in the amount, duration and cost of potentially preventable hospitalisation for chronic conditions among Aboriginal and non-Aboriginal Australians: a period prevalence study of linked public hospital data. <i>BMJ Open</i> , 2017, 7, e017331.	1.9	15
92	Randomised clinical trials in perinatal health care: a cost-effective investment. <i>Medical Journal of Australia</i> , 2017, 207, 289-293.	1.7	9
93	What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia. <i>Cost Effectiveness and Resource Allocation</i> , 2016, 14, 11.	1.5	17
94	Option B+ for the prevention of mother-to-child transmission of HIV infection in developing countries: a review of published cost-effectiveness analyses. <i>Health Policy and Planning</i> , 2016, 31, 1133-1141.	2.7	20
95	Strategies for implementing shared decision making in elective surgery by healthcare practitioners: a systematic review protocol. <i>JBIC Database of Systematic Reviews and Implementation Reports</i> , 2016, 14, 100-108.	1.7	2
96	Model Validation: Has it's Time Come?. <i>Pharmacoeconomics</i> , 2016, 34, 829-831.	3.3	4
97	Translating a health service intervention into a rural setting: lessons learned. <i>BMC Health Services Research</i> , 2016, 16, 62.	2.2	12
98	Improving the planning of the GP workforce in Australia: a simulation model incorporating work transitions, health need and service usage. <i>Human Resources for Health</i> , 2016, 14, 13.	3.1	15
99	A comparison of propensity score-based approaches to health service evaluation: a case study of a preoperative physician-led clinic for high-risk surgical patients. <i>Journal of Evaluation in Clinical Practice</i> , 2016, 22, 761-770.	1.8	2
100	Variation in Clinical Practice: A Priority Setting Approach to the Staged Funding of Quality Improvement. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 21-27.	2.1	12
101	Should the Lambda (λ) Remain Silent?. <i>Pharmacoeconomics</i> , 2016, 34, 323-329.	3.3	6
102	Frailty and health service use in rural South Australia. <i>Archives of Gerontology and Geriatrics</i> , 2016, 62, 53-58.	3.0	24
103	INFORMING DISINVESTMENT WITH LIMITED EVIDENCE: COBALAMIN DEFICIENCY IN THE FATIGUED. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 188-196.	0.5	1
104	DOES ONE SIZE FIT ALL? COST UTILITY ANALYSES OF ALTERNATIVE MAMMOGRAPHIC FOLLOW-UP SCHEDULES, BY RISK OF RECURRENCE. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 281-288.	0.5	9
105	Exploring Structural Uncertainty in Model-Based Economic Evaluations. <i>Pharmacoeconomics</i> , 2015, 33, 435-443.	3.3	24
106	The implementation of ergonomics advice and the stage of change approach. <i>Applied Ergonomics</i> , 2015, 51, 370-376.	3.1	33
107	Cost-Effectiveness of Noninvasive Central Blood Pressure Monitoring in the Diagnosis of Hypertension. <i>American Journal of Hypertension</i> , 2015, 28, 604-614.	2.0	15
108	Process Mining for Clinical Processes. <i>ACM Transactions on Management Information Systems</i> , 2015, 5, 1-18.	2.8	101

#	ARTICLE	IF	CITATIONS
109	Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?. <i>Pharmacoeconomics</i> , 2015, 33, 1281-1288.	3.3	4
110	Practice nurse involvement in general practice clinical care: policy and funding issues need resolution. <i>Australian Health Review</i> , 2014, 38, 301.	1.1	18
111	Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysis. <i>BMC Family Practice</i> , 2014, 15, 10.	2.9	5
112	A Patient-Level Calibration Framework for Evaluating Surveillance Strategies: A Case Study of Mammographic Follow-Up After Early Breast Cancer. <i>Value in Health</i> , 2014, 17, 669-678.	0.3	8
113	Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?. <i>Pharmacoeconomics</i> , 2014, 32, 315-318.	3.3	10
114	When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES. <i>Pharmacoeconomics</i> , 2014, 32, 547-558.	3.3	51
115	Managing high-risk surgical patients: modifiable comorbidities matter. <i>ANZ Journal of Surgery</i> , 2014, 84, 925-931.	0.7	6
116	APPLYING RISK ADJUSTED COST-EFFECTIVENESS (RACE) ANALYSIS TO HOSPITALS: ESTIMATING THE COSTS AND CONSEQUENCES OF VARIATION IN CLINICAL PRACTICE. <i>Health Economics (United Kingdom)</i> , 2013, 22, 631-642.	1.7	15
117	Model Performance Evaluation (Validation and Calibration) in Model-based Studies of Therapeutic Interventions for Cardiovascular Diseases. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 85-93.	2.1	18
118	A Model-Based Economic Evaluation of Improved Primary Care Management of Patients with Type 2 Diabetes in Australia. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 661-670.	2.1	6
119	Development and calibration of a constrained resource health outcomes simulation model of hospital-based glaucoma services. <i>Health Systems</i> , 2013, 2, 181-197.	1.2	4
120	Implementation of interventions to prevent musculoskeletal injury at work – lost in translation?. <i>Physical Therapy Reviews</i> , 2013, 18, 344-349.	0.8	6
121	Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. <i>Pharmacogenomics</i> , 2013, 14, 2013-2021.	1.3	33
122	Accounting for Costs, QALYs, and Capacity Constraints. <i>Medical Decision Making</i> , 2013, 33, 986-997.	2.4	15
123	Improving the Accuracy and Comparability of Model-Based Economic Evaluations of Health Technologies for Reimbursement Decisions. <i>Medical Decision Making</i> , 2013, 33, 325-332.	2.4	31
124	Model Parameter Estimation and Uncertainty Analysis. <i>Medical Decision Making</i> , 2012, 32, 722-732.	2.4	564
125	Lifetime Cost-Utility Analyses of Deferasirox in Beta-Thalassaemia Patients with Chronic Iron Overload. <i>Clinical Drug Investigation</i> , 2012, 32, 805-815.	2.2	15
126	Modeling Using Discrete Event Simulation. <i>Medical Decision Making</i> , 2012, 32, 701-711.	2.4	189

#	ARTICLE	IF	CITATIONS
127	Evaluating the effects of variation in clinical practice: a risk adjusted cost-effectiveness (RAC-E) analysis of acute stroke services. BMC Health Services Research, 2012, 12, 266.	2.2	7
128	Modeling using Discrete Event Simulation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Value in Health, 2012, 15, 821-827.	0.3	166
129	Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value in Health, 2012, 15, 835-842.	0.3	478
130	Monitoring progress in the management of hip fractures in South Australia, Australia. Archives of Osteoporosis, 2012, 7, 267-273.	2.4	6
131	A Critical Review of Model-Based Economic Studies of Depression. Pharmacoeconomics, 2012, 30, 461-482.	3.3	28
132	The LINKIN Health Census process: design and implementation. BMC Health Services Research, 2012, 12, 321.	2.2	10
133	Home Videophones Improve Direct Observation in Tuberculosis Treatment: A Mixed Methods Evaluation. PLoS ONE, 2012, 7, e50155.	2.5	59
134	A proposed model for economic evaluations of major depressive disorder. European Journal of Health Economics, 2012, 13, 501-510.	2.8	16
135	A model-based evaluation of collaborative care in management of patients with type 2 diabetes in Australia: an initial report. Australian Health Review, 2012, 36, 258.	1.1	4
136	The Cost of Treating Advanced Non-Small Cell Lung Cancer: Estimates from the Chinese Experience. PLoS ONE, 2012, 7, e48323.	2.5	36
137	Evaluation of collaborative models of care in the management of patients with depression: protocol and progress. Mental Health in Family Medicine, 2012, 9, 91-7.	0.2	1
138	Calibrating Models in Economic Evaluation. Pharmacoeconomics, 2011, 29, 51-62.	3.3	52
139	Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions. Pharmacoeconomics, 2011, 29, 823-825.	3.3	16
140	Calibrating Models in Economic Evaluation. Pharmacoeconomics, 2011, 29, 35-49.	3.3	123
141	Sugar consumption from beverages and the potential effects of a text-based information label. Australian and New Zealand Journal of Public Health, 2011, 35, 88-89.	1.8	8
142	Is different better? Models of teaching and their influence on the net financial outcome for general practice teaching posts. BMC Medical Education, 2011, 11, 45.	2.4	6
143	Cost-Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Solid Tumors. Journal of Clinical Oncology, 2011, 29, 3270-3277.	1.6	60
144	Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. British Journal of General Practice, 2011, 61, e620-e627.	1.4	14

#	ARTICLE	IF	CITATIONS
145	The efficient price: an opportunity for funding reform. Australian Health Review, 2011, 35, 501.	1.1	4
146	To teach or not to teach? A cost-benefit analysis of teaching in private general practice. Medical Journal of Australia, 2010, 193, 608-613.	1.7	18
147	Decision Modeling to Inform Decision Making: Seeing the Wood for the Trees. Medical Decision Making, 2010, 30, E20-E22.	2.4	4
148	Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. BMJ: British Medical Journal, 2010, 341, c5132-c5132.	2.3	30
149	A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. International Journal of Cardiology, 2010, 140, 315-322.	1.7	10
150	A qualitative study of sustainability and vulnerability in Australian telehealth services. Studies in Health Technology and Informatics, 2010, 161, 190-201.	0.3	23
151	Identifying existing health care services that do not provide value for money. Medical Journal of Australia, 2009, 190, 269-273.	1.7	108
152	A Hybrid Cohort Individual Sampling Natural History Model of Age-Related Macular Degeneration: Assessing the Cost-Effectiveness of Screening Using Probabilistic Calibration. Medical Decision Making, 2009, 29, 304-316.	2.4	16
153	Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). Journal of Evaluation in Clinical Practice, 2009, 15, 299-306.	1.8	108
154	Informing disinvestment through cost-effectiveness modelling. Applied Health Economics and Health Policy, 2009, 7, 1-9.	2.1	21
155	Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Research and Treatment, 2008, 108, 375-387.	2.5	33
156	Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. European Journal of Health Economics, 2008, 9, 171-183.	2.8	31
157	Economic Evaluations in Rheumatoid Arthritis. Pharmacoeconomics, 2008, 26, 395-408.	3.3	27
158	Cost-utility analysis of screening high-risk groups for anal cancer. Journal of Public Health, 2008, 30, 293-304.	1.8	35
159	Modelling the Expected Net Benefits of Interventions to Reduce the Burden of Medication Errors. Journal of Health Services Research and Policy, 2008, 13, 85-91.	1.7	41
160	Cost-effectiveness of letrozole, anastrozole and exemestane for early adjuvant breast cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 2007, 7, 143-153.	1.4	4
161	A Critique and Impact Analysis of Decision Modeling Assumptions. Medical Decision Making, 2007, 27, 491-499.	2.4	18
162	A prospective hazard and improvement analytic approach to predicting the effectiveness of medication error interventions. Safety Science, 2007, 45, 523-539.	4.9	21

#	ARTICLE	IF	CITATIONS
163	Aromatase Inhibitors in Breast Cancer. <i>Pharmacoeconomics</i> , 2006, 24, 215-232.	3.3	23
164	Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy. <i>Pharmacoeconomics</i> , 2006, 24, 237-250.	3.3	35
165	Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. <i>American Journal of Managed Care</i> , 2006, 12, 374-86.	1.1	34
166	Developing a relativities approach to valuing the prevention of non-fatal work-related accidents and ill health. <i>Health Economics (United Kingdom)</i> , 2005, 14, 1103-1115.	1.7	4
167	Cost-effectiveness of letrozole in the treatment of advanced breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 383-391.	1.4	1
168	Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. <i>Health Economics (United Kingdom)</i> , 2003, 12, 837-848.	1.7	111
169	Tamoxifen Plus Chemotherapy versus Tamoxifen Alone as Adjuvant Therapies for Node-Positive Postmenopausal Women with Early Breast Cancer. <i>Pharmacoeconomics</i> , 2002, 20, 119-137.	3.3	23
170	Planning the efficient allocation of research funds: an adapted application of a non-parametric Bayesian value of information analysis. <i>Health Policy</i> , 2002, 61, 329-347.	3.0	22
171	A model for analyzing the cost of the main clinical events after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2001, 20, 474-482.	0.6	17
172	Economic evaluation alongside-of-1 trials: getting closer to the margin. <i>Health Economics (United Kingdom)</i> , 2001, 15, 107-115.	1.7	15
173	Cost analysis of a hospital-at-home initiative using discrete event simulation. <i>Journal of Health Services Research and Policy</i> , 2001, 6, 14-22.	1.7	13
174	Using modelling in a phased approach to the economic evaluation of adjuvant therapy for early breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999, 32, 95-103.	4.4	2
175	Selecting a decision model for economic evaluation: a case study and review. <i>Health Care Management Science</i> , 1998, 1, 133-140.	2.6	62
176	Models for delivery and co-ordination of primary or secondary health care (or both) to older adults living in aged care facilities. <i>The Cochrane Library</i> , 0, .	2.8	1